EVM
RVNC

Eaton Vance Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Eaton Vance Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-405
Closed -$11K – 3056
2021
Q1 		$11K Buy
+405
New +$11.2K ﹤0.01% 2345

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Eaton Vance Management's RVNC Position: Q2 2021 in Review

Eaton Vance Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2021, closing a stake of 405 shares — an estimated $11K sold.

Eaton Vance Management first reported a position in RVNC in Q1 2021 and held it in 1 quarter. The position peaked at $11K in Q1 2021. 161 funds tracked by Wall St. Rank hold RVNC as of Q2 2021.

  • Eaton Vance Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Eaton Vance Management sold 405 Revance Therapeutics, Inc. shares in Q2 2021, an estimated $11K.
  • Eaton Vance Management first reported a position in Revance Therapeutics, Inc. in Q1 2021 and held it in 1 quarter.
  • Eaton Vance Management's Revance Therapeutics, Inc. position peaked at $11K in Q1 2021.
  • 161 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2021.

Based on Eaton Vance Management's 13F filing for Q2 2021, filed 16 Aug 2021.